secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001193125-25-048529
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio: taletrectinib NDA Priority Review, $250M financing, Q4 net loss $49.4M
--------------------------------------------------------------------------------

- FDA accepted NDA for taletrectinib with Priority Review; PDUFA goal date June 23, 2025 for advanced ROS1+ NSCLC.
- Secured up to $250M non-dilutive financings from Sagard: $150M royalty interest plus $50M debt upon FDA approval.
- Q4 net loss $49.4M ($0.15/sh) vs $13.8M ($0.06) in Q4 2023; R&D and SG&A rose due to AnHeart acquisition.
- China NMPA approved taletrectinib Jan 2025 (Innovent commercializing); Nippon Kayaku submitted MAA in Japan.
- Launched U.S. Expanded Access Program for taletrectinib in February 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525048529/0001193125-25-048529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525048529/d910737d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-048529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer